Phase 3 Clinical Trials With Primary Completion Dates in January 2023
This is a list of Phase 3 trials with primary completion dates in January 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2023-01-01 | Phase 3 | NCT04776746 | Open-Label Extension Study of Trofinetide for Rett Syndrome |
| ACHV | Achieve Life Sciences, Inc. | 2023-01-01 | Phase 3 | NCT05206370 | A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers |
| BHVN | Biohaven Ltd. | 2023-01-01 | Phase 3 | NCT04649242 | Randomized Study in Children and Adolescents With Migraine: Acute Treatment |
| CLVSQ | Clovis Oncology, Inc. | 2023-01-01 | Phase 3 | NCT04227522 | Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients |
| CYDY | CytoDyn Inc. | 2023-01-01 | Phase 3 | NCT04901676 | Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia |
| IVBXF | Innovent Biologics, Inc. | 2023-01-01 | Phase 3 | NCT03700476 | Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma |
| NEPH | Nephros, Inc. | 2023-01-01 | Phase 3 | NCT03769441 | Effect of Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation |
| STMH | Stem Holdings, Inc. | 2023-01-01 | Phase 3 | NCT05004324 | Safety and Efficacy of FURESTEM-AD Inj. for Moderate to Severe Atopic Dermatitis (AD) |